<b>Background:</b> Alectinib, a highly selective inhibitor of ALK, is currently used in the first-line setting of untreated advanced ALK-positive NSCLC and in the second-line setting of crizotinib-resistant ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.